FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Developers look for rules to govern name game

The RPM Report focuses on a new effort to revise and improve the way the FDA approves proposed proprietary drug names. The agency kicks back about 40 percent of the brand names suggested by sponsors, creating a great deal of frustration with the process. The industry wants more predictability and more insight into what it needs to do to get an approval. But a new pilot program aimed at improving the process is instead raising fears that the name-game will only grow more complex.

- read the story from RPM Report

Related Articles:
Drug name psychology, or the power of Z
Drug marketing costs double R&D
IMS lists best drug launches of all time

More stories about sales and marketing   drug marketing   FDA  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 38 + 32?
To combat spam, please solve the math question above.